Selective immune cell removal may tame transplant complications

NCT ID NCT02220985

Completed Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemotherapy and radiation before transplant. The goal was to reduce GVHD while keeping the donor cells' ability to fight infections and cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Allogeneic hematopoietic stem cell transplantation with selective depletion of CD45RA+ T cells
What this could lead to: If successful, this approach could reduce the severity of graft-versus-host disease while preserving the donor cells' ability to fight infections and cancer, improving outcomes for stem cell transplant recipients.
What could go wrong: This is a phase II trial with a moderate number of participants, so results may not be definitive. The procedure is complex and carries risks such as graft failure, infection, or relapse of the underlying cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute leukemia of ambiguous lineage acute lymphoblastic leukemia acute myeloid leukemia acute undifferentiated leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive Blastic Plasmacytoid Dendritic Cell Neoplasm CD4+/CD56+ hematodermic neoplasm childhood acute lymphoblastic leukemia childhood acute myeloid leukemia chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive leukemia, myeloid, accelerated-phase lymphoblastic lymphoma myelodysplastic syndrome myelodysplastic syndrome with excess blasts myelodysplastic syndrome with excess blasts-1 myelodysplastic syndrome with excess blasts-2 Precursor Cell Lymphoblastic Leukemia-Lymphoma graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE ACUTE BIPHENOTYPIC LEUKEMIA ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION ACUTE MYELOID LEUKEMIA IN REMISSION ACUTE UNDIFFERENTIATED LEUKEMIA ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENT BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION CHILDHOOD ACUTE MYELOID LEUKEMIA IN REMISSION DONOR LYMPHOBLASTIC LYMPHOMA MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1 MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-2 RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.